Page last updated: 2024-12-07
dihydroisotanshinone i
Description
Dihydroisotanshinone I (DHTS-I) is a natural compound isolated from the root of the medicinal herb Salvia miltiorrhiza (Danshen), traditionally used in Traditional Chinese Medicine for the treatment of cardiovascular diseases. It has garnered significant research interest due to its diverse pharmacological activities, including antioxidant, anti-inflammatory, anti-cancer, and neuroprotective effects. DHTS-I has been shown to inhibit the production of reactive oxygen species (ROS), reduce inflammation by suppressing the production of pro-inflammatory cytokines, and induce apoptosis in cancer cells. It is also reported to protect neurons from damage caused by oxidative stress. The mechanism of action of DHTS-I involves multiple targets, including the activation of Nrf2, a key transcription factor involved in antioxidant defense, and the inhibition of various signaling pathways associated with inflammation and cancer development. DHTS-I is currently under investigation for its potential therapeutic applications in various diseases, including cardiovascular diseases, cancer, neurodegenerative disorders, and inflammatory conditions.'
dihydroisotanshinone I: isolated from the root of Salvia miltiorrhiza Bunge; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Flora | Rank | Flora Definition | Family | Family Definition |
Salvia | genus | A genus in the mint family (LAMIACEAE).[MeSH] | Lamiaceae | The mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH] |
Salvia miltiorrhiza | species | A plant species which is known as an Oriental traditional medicinal plant.[MeSH] | Lamiaceae | The mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH] |
Cross-References
ID Source | ID |
PubMed CID | 89406 |
SCHEMBL ID | 13568194 |
MeSH ID | M0135498 |
Synonyms (18)
Synonym |
dihydroisotanshinone i |
4,8-dimethyl-8,9-dihydronaphtho[2,1-f][1]benzofuran-7,11-dione |
20958-18-3 |
phenanthro(3,2-b)furan-7,11-dione, 8,9-dihydro-4,8-dimethyl- |
4,8-dimethyl-8,9-dihydrophenanthro[3,2-b]furan-7,11-dione |
SCHEMBL13568194 |
AC-35146 |
4,8-dimethyl-8,9-dihydrophenanthro[3,2-b]furan-7,11-dione # |
phenanthro[3,2-b]furan-7,11-dione, 8,9-dihydro-4,8-dimethyl- |
KXNYCALHDXGJSF-UHFFFAOYSA-N |
AKOS028109839 |
CS-6505 |
HY-B1919 |
FT-0766994 |
DTXSID60943247 |
4,8-dimethyl-7h,8h,9h,11h-phenanthro[3,2-b]furan-7,11-dione |
PD078596 |
FS-6927 |
Research Excerpts
Overview
Dihydroisotanshinone I is a phenanthrenequinone derivative isolated from the roots of Salvia trijuga Diels.
Compound-Compound Interactions
Excerpt | Reference | Relevance |
" Despite that sophisticated techniques of radiotherapy and radiation combined with chemotherapy were applied to the patients, some tumors may recur." | ( Dihydroisotanshinone I combined with radiation inhibits the migration ability of prostate cancer cells through DNA damage and CCL2 pathway. Cheng, YC; Lee, IY; Lin, CL; Lin, WY; Lin, YS; Lin, YY; Shu, LH; Wu, CY; Yang, YH, 2018) | 1.92 |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 1 (11.11) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 4 (44.44) | 24.3611 |
2020's | 3 (33.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.82
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.82 (24.57) | Research Supply Index | 2.30 (2.92) | Research Growth Index | 5.12 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |